

Global Long-acting Injectable Antipsychotics (LAIs) Market Growth 2024-2030

<https://marketpublishers.com/r/GE85941B8D5BEN.html>

Date: July 2024

Pages: 105

Price: US\$ 3,660.00 (Single User License)

ID: GE85941B8D5BEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Long-acting injectable (LAI) antipsychotics are unique medication formulations used in psychiatric pharmacy to help improve patient outcomes. They offer several benefits compared to oral therapy, including confirmed patient adherence, consistent drug delivery, predictable bioavailability, and prevention of antipsychotic overdose.

The global Long-acting Injectable Antipsychotics (LAIs) market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Long-acting Injectable Antipsychotics (LAIs) Industry Forecast” looks at past sales and reviews total world Long-acting Injectable Antipsychotics (LAIs) sales in 2023, providing a comprehensive analysis by region and market sector of projected Long-acting Injectable Antipsychotics (LAIs) sales for 2024 through 2030. With Long-acting Injectable Antipsychotics (LAIs) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Long-acting Injectable Antipsychotics (LAIs) industry.

This Insight Report provides a comprehensive analysis of the global Long-acting Injectable Antipsychotics (LAIs) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting Injectable Antipsychotics (LAIs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better

understand these firms' unique position in an accelerating global Long-acting Injectable Antipsychotics (LAIs) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting Injectable Antipsychotics (LAIs) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Injectable Antipsychotics (LAIs).

United States market for Long-acting Injectable Antipsychotics (LAIs) is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Long-acting Injectable Antipsychotics (LAIs) is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Long-acting Injectable Antipsychotics (LAIs) is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Long-acting Injectable Antipsychotics (LAIs) players cover Otsuka Pharmaceutical, CHEPLAPHARM Arzneimittel GmbH, Alkermes Pharma Ireland Limited, Essential Pharma, Janssen Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Injectable Antipsychotics (LAIs) market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

First-generation

Second-generation

Segmentation by Application:

Schizophrenia

Bipolar Disorder

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Otsuka Pharmaceutical

CHEPLAPHARM Arzneimittel GmbH

Alkermes Pharma Ireland Limited

Essential Pharma

Janssen Pharmaceuticals

Indivior UK Limited

Qilu Pharmaceutical

Lvye Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Long-acting Injectable Antipsychotics (LAIs) market?

What factors are driving Long-acting Injectable Antipsychotics (LAIs) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Long-acting Injectable Antipsychotics (LAIs) market opportunities vary by end market size?

How does Long-acting Injectable Antipsychotics (LAIs) break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Long-acting Injectable Antipsychotics (LAIs) Annual Sales 2019-2030
- 2.1.2 World Current & Future Analysis for Long-acting Injectable Antipsychotics (LAIs) by Geographic Region, 2019, 2023 & 2030
- 2.1.3 World Current & Future Analysis for Long-acting Injectable Antipsychotics (LAIs) by Country/Region, 2019, 2023 & 2030

2.2 Long-acting Injectable Antipsychotics (LAIs) Segment by Type

- 2.2.1 First-generation
- 2.2.2 Second-generation

2.3 Long-acting Injectable Antipsychotics (LAIs) Sales by Type

- 2.3.1 Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2019-2024)
- 2.3.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue and Market Share by Type (2019-2024)
- 2.3.3 Global Long-acting Injectable Antipsychotics (LAIs) Sale Price by Type (2019-2024)

2.4 Long-acting Injectable Antipsychotics (LAIs) Segment by Application

- 2.4.1 Schizophrenia
- 2.4.2 Bipolar Disorder
- 2.4.3 Other

2.5 Long-acting Injectable Antipsychotics (LAIs) Sales by Application

- 2.5.1 Global Long-acting Injectable Antipsychotics (LAIs) Sale Market Share by Application (2019-2024)
- 2.5.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue and Market Share

by Application (2019-2024)

2.5.3 Global Long-acting Injectable Antipsychotics (LAIs) Sale Price by Application (2019-2024)

3 GLOBAL BY COMPANY

3.1 Global Long-acting Injectable Antipsychotics (LAIs) Breakdown Data by Company

3.1.1 Global Long-acting Injectable Antipsychotics (LAIs) Annual Sales by Company (2019-2024)

3.1.2 Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Company (2019-2024)

3.2 Global Long-acting Injectable Antipsychotics (LAIs) Annual Revenue by Company (2019-2024)

3.2.1 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Company (2019-2024)

3.2.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Company (2019-2024)

3.3 Global Long-acting Injectable Antipsychotics (LAIs) Sale Price by Company

3.4 Key Manufacturers Long-acting Injectable Antipsychotics (LAIs) Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Long-acting Injectable Antipsychotics (LAIs) Product Location Distribution

3.4.2 Players Long-acting Injectable Antipsychotics (LAIs) Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR LONG-ACTING INJECTABLE ANTIPSYCHOTICS (LAIS) BY GEOGRAPHIC REGION

4.1 World Historic Long-acting Injectable Antipsychotics (LAIs) Market Size by Geographic Region (2019-2024)

4.1.1 Global Long-acting Injectable Antipsychotics (LAIs) Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Long-acting Injectable Antipsychotics (LAIs) Annual Revenue by Geographic Region (2019-2024)

4.2 World Historic Long-acting Injectable Antipsychotics (LAIs) Market Size by

Country/Region (2019-2024)

4.2.1 Global Long-acting Injectable Antipsychotics (LAIs) Annual Sales by Country/Region (2019-2024)

4.2.2 Global Long-acting Injectable Antipsychotics (LAIs) Annual Revenue by Country/Region (2019-2024)

4.3 Americas Long-acting Injectable Antipsychotics (LAIs) Sales Growth

4.4 APAC Long-acting Injectable Antipsychotics (LAIs) Sales Growth

4.5 Europe Long-acting Injectable Antipsychotics (LAIs) Sales Growth

4.6 Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales Growth

5 AMERICAS

5.1 Americas Long-acting Injectable Antipsychotics (LAIs) Sales by Country

5.1.1 Americas Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2024)

5.1.2 Americas Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2019-2024)

5.2 Americas Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2019-2024)

5.3 Americas Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Long-acting Injectable Antipsychotics (LAIs) Sales by Region

6.1.1 APAC Long-acting Injectable Antipsychotics (LAIs) Sales by Region (2019-2024)

6.1.2 APAC Long-acting Injectable Antipsychotics (LAIs) Revenue by Region (2019-2024)

6.2 APAC Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2019-2024)

6.3 APAC Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2019-2024)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Long-acting Injectable Antipsychotics (LAIs) by Country

7.1.1 Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2024)

7.1.2 Europe Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2019-2024)

7.2 Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2019-2024)

7.3 Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2019-2024)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) by Country

8.1.1 Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2024)

8.1.2 Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2019-2024)

8.2 Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2019-2024)

8.3 Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2019-2024)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Long-acting Injectable Antipsychotics (LAIs)

10.3 Manufacturing Process Analysis of Long-acting Injectable Antipsychotics (LAIs)

10.4 Industry Chain Structure of Long-acting Injectable Antipsychotics (LAIs)

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Long-acting Injectable Antipsychotics (LAIs) Distributors

11.3 Long-acting Injectable Antipsychotics (LAIs) Customer

12 WORLD FORECAST REVIEW FOR LONG-ACTING INJECTABLE ANTIPSYCHOTICS (LAIS) BY GEOGRAPHIC REGION

12.1 Global Long-acting Injectable Antipsychotics (LAIs) Market Size Forecast by Region

12.1.1 Global Long-acting Injectable Antipsychotics (LAIs) Forecast by Region (2025-2030)

12.1.2 Global Long-acting Injectable Antipsychotics (LAIs) Annual Revenue Forecast by Region (2025-2030)

12.2 Americas Forecast by Country (2025-2030)

12.3 APAC Forecast by Region (2025-2030)

12.4 Europe Forecast by Country (2025-2030)

12.5 Middle East & Africa Forecast by Country (2025-2030)

12.6 Global Long-acting Injectable Antipsychotics (LAIs) Forecast by Type (2025-2030)

12.7 Global Long-acting Injectable Antipsychotics (LAIs) Forecast by Application (2025-2030)

13 KEY PLAYERS ANALYSIS

13.1 Otsuka Pharmaceutical

- 13.1.1 Otsuka Pharmaceutical Company Information
- 13.1.2 Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications
- 13.1.3 Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.1.4 Otsuka Pharmaceutical Main Business Overview
- 13.1.5 Otsuka Pharmaceutical Latest Developments
- 13.2 CHEPLAPHARM Arzneimittel GmbH
 - 13.2.1 CHEPLAPHARM Arzneimittel GmbH Company Information
 - 13.2.2 CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications
 - 13.2.3 CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.2.4 CHEPLAPHARM Arzneimittel GmbH Main Business Overview
 - 13.2.5 CHEPLAPHARM Arzneimittel GmbH Latest Developments
- 13.3 Alkermes Pharma Ireland Limited
 - 13.3.1 Alkermes Pharma Ireland Limited Company Information
 - 13.3.2 Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications
 - 13.3.3 Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.3.4 Alkermes Pharma Ireland Limited Main Business Overview
 - 13.3.5 Alkermes Pharma Ireland Limited Latest Developments
- 13.4 Essential Pharma
 - 13.4.1 Essential Pharma Company Information
 - 13.4.2 Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications
 - 13.4.3 Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.4.4 Essential Pharma Main Business Overview
 - 13.4.5 Essential Pharma Latest Developments
- 13.5 Janssen Pharmaceuticals
 - 13.5.1 Janssen Pharmaceuticals Company Information
 - 13.5.2 Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications
 - 13.5.3 Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.5.4 Janssen Pharmaceuticals Main Business Overview
 - 13.5.5 Janssen Pharmaceuticals Latest Developments

13.6 Indivior UK Limited

13.6.1 Indivior UK Limited Company Information

13.6.2 Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications

13.6.3 Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, Price and Gross Margin (2019-2024)

13.6.4 Indivior UK Limited Main Business Overview

13.6.5 Indivior UK Limited Latest Developments

13.7 Qilu Pharmaceutical

13.7.1 Qilu Pharmaceutical Company Information

13.7.2 Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications

13.7.3 Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, Price and Gross Margin (2019-2024)

13.7.4 Qilu Pharmaceutical Main Business Overview

13.7.5 Qilu Pharmaceutical Latest Developments

13.8 Lvye Pharmaceutical

13.8.1 Lvye Pharmaceutical Company Information

13.8.2 Lvye Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications

13.8.3 Lvye Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, Price and Gross Margin (2019-2024)

13.8.4 Lvye Pharmaceutical Main Business Overview

13.8.5 Lvye Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Long-acting Injectable Antipsychotics (LAIs) Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Table 2. Long-acting Injectable Antipsychotics (LAIs) Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)
- Table 3. Major Players of First-generation
- Table 4. Major Players of Second-generation
- Table 5. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2019-2024) & (K Units)
- Table 6. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2019-2024)
- Table 7. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Type (2019-2024) & (\$ million)
- Table 8. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Type (2019-2024)
- Table 9. Global Long-acting Injectable Antipsychotics (LAIs) Sale Price by Type (2019-2024) & (US\$/Unit)
- Table 10. Global Long-acting Injectable Antipsychotics (LAIs) Sale by Application (2019-2024) & (K Units)
- Table 11. Global Long-acting Injectable Antipsychotics (LAIs) Sale Market Share by Application (2019-2024)
- Table 12. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Application (2019-2024) & (\$ million)
- Table 13. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Application (2019-2024)
- Table 14. Global Long-acting Injectable Antipsychotics (LAIs) Sale Price by Application (2019-2024) & (US\$/Unit)
- Table 15. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Company (2019-2024) & (K Units)
- Table 16. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Company (2019-2024)
- Table 17. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Company (2019-2024) & (\$ millions)
- Table 18. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Company (2019-2024)
- Table 19. Global Long-acting Injectable Antipsychotics (LAIs) Sale Price by Company

(2019-2024) & (US\$/Unit)

Table 20. Key Manufacturers Long-acting Injectable Antipsychotics (LAIs) Producing Area Distribution and Sales Area

Table 21. Players Long-acting Injectable Antipsychotics (LAIs) Products Offered

Table 22. Long-acting Injectable Antipsychotics (LAIs) Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 23. New Products and Potential Entrants

Table 24. Market M&A Activity & Strategy

Table 25. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Geographic Region (2019-2024) & (K Units)

Table 26. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share Geographic Region (2019-2024)

Table 27. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 28. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Geographic Region (2019-2024)

Table 29. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Country/Region (2019-2024) & (K Units)

Table 30. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country/Region (2019-2024)

Table 31. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Country/Region (2019-2024) & (\$ millions)

Table 32. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Country/Region (2019-2024)

Table 33. Americas Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2024) & (K Units)

Table 34. Americas Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country (2019-2024)

Table 35. Americas Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2019-2024) & (\$ millions)

Table 36. Americas Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2019-2024) & (K Units)

Table 37. Americas Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2019-2024) & (K Units)

Table 38. APAC Long-acting Injectable Antipsychotics (LAIs) Sales by Region (2019-2024) & (K Units)

Table 39. APAC Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Region (2019-2024)

Table 40. APAC Long-acting Injectable Antipsychotics (LAIs) Revenue by Region

(2019-2024) & (\$ millions)

Table 41. APAC Long-acting Injectable Antipsychotics (LAIs) Sales by Type

(2019-2024) & (K Units)

Table 42. APAC Long-acting Injectable Antipsychotics (LAIs) Sales by Application

(2019-2024) & (K Units)

Table 43. Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Country

(2019-2024) & (K Units)

Table 44. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue by Country

(2019-2024) & (\$ millions)

Table 45. Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Type

(2019-2024) & (K Units)

Table 46. Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Application

(2019-2024) & (K Units)

Table 47. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales by

Country (2019-2024) & (K Units)

Table 48. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Revenue

Market Share by Country (2019-2024)

Table 49. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales by

Type (2019-2024) & (K Units)

Table 50. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales by

Application (2019-2024) & (K Units)

Table 51. Key Market Drivers & Growth Opportunities of Long-acting Injectable

Antipsychotics (LAIs)

Table 52. Key Market Challenges & Risks of Long-acting Injectable Antipsychotics

(LAIs)

Table 53. Key Industry Trends of Long-acting Injectable Antipsychotics (LAIs)

Table 54. Long-acting Injectable Antipsychotics (LAIs) Raw Material

Table 55. Key Suppliers of Raw Materials

Table 56. Long-acting Injectable Antipsychotics (LAIs) Distributors List

Table 57. Long-acting Injectable Antipsychotics (LAIs) Customer List

Table 58. Global Long-acting Injectable Antipsychotics (LAIs) Sales Forecast by Region

(2025-2030) & (K Units)

Table 59. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Forecast by

Region (2025-2030) & (\$ millions)

Table 60. Americas Long-acting Injectable Antipsychotics (LAIs) Sales Forecast by

Country (2025-2030) & (K Units)

Table 61. Americas Long-acting Injectable Antipsychotics (LAIs) Annual Revenue

Forecast by Country (2025-2030) & (\$ millions)

Table 62. APAC Long-acting Injectable Antipsychotics (LAIs) Sales Forecast by Region

(2025-2030) & (K Units)

Table 63. APAC Long-acting Injectable Antipsychotics (LAIs) Annual Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 64. Europe Long-acting Injectable Antipsychotics (LAIs) Sales Forecast by Country (2025-2030) & (K Units)

Table 65. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 66. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales Forecast by Country (2025-2030) & (K Units)

Table 67. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 68. Global Long-acting Injectable Antipsychotics (LAIs) Sales Forecast by Type (2025-2030) & (K Units)

Table 69. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Forecast by Type (2025-2030) & (\$ millions)

Table 70. Global Long-acting Injectable Antipsychotics (LAIs) Sales Forecast by Application (2025-2030) & (K Units)

Table 71. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Forecast by Application (2025-2030) & (\$ millions)

Table 72. Otsuka Pharmaceutical Basic Information, Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base, Sales Area and Its Competitors

Table 73. Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications

Table 74. Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 75. Otsuka Pharmaceutical Main Business

Table 76. Otsuka Pharmaceutical Latest Developments

Table 77. CHEPLAPHARM Arzneimittel GmbH Basic Information, Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base, Sales Area and Its Competitors

Table 78. CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications

Table 79. CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 80. CHEPLAPHARM Arzneimittel GmbH Main Business

Table 81. CHEPLAPHARM Arzneimittel GmbH Latest Developments

Table 82. Alkermes Pharma Ireland Limited Basic Information, Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base, Sales Area and Its Competitors

Table 83. Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs)

Product Portfolios and Specifications

Table 84. Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 85. Alkermes Pharma Ireland Limited Main Business

Table 86. Alkermes Pharma Ireland Limited Latest Developments

Table 87. Essential Pharma Basic Information, Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base, Sales Area and Its Competitors

Table 88. Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications

Table 89. Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 90. Essential Pharma Main Business

Table 91. Essential Pharma Latest Developments

Table 92. Janssen Pharmaceuticals Basic Information, Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base, Sales Area and Its Competitors

Table 93. Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications

Table 94. Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 95. Janssen Pharmaceuticals Main Business

Table 96. Janssen Pharmaceuticals Latest Developments

Table 97. Indivior UK Limited Basic Information, Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base, Sales Area and Its Competitors

Table 98. Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications

Table 99. Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 100. Indivior UK Limited Main Business

Table 101. Indivior UK Limited Latest Developments

Table 102. Qilu Pharmaceutical Basic Information, Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base, Sales Area and Its Competitors

Table 103. Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications

Table 104. Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 105. Qilu Pharmaceutical Main Business

Table 106. Qilu Pharmaceutical Latest Developments

Table 107. Lvye Pharmaceutical Basic Information, Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base, Sales Area and Its Competitors

Table 108. Lvy Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications

Table 109. Lvy Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 110. Lvy Pharmaceutical Main Business

Table 111. Lvy Pharmaceutical Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Long-acting Injectable Antipsychotics (LAIs)

Figure 2. Long-acting Injectable Antipsychotics (LAIs) Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Long-acting Injectable Antipsychotics (LAIs) Sales Growth Rate 2019-2030 (K Units)

Figure 7. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate 2019-2030 (\$ millions)

Figure 8. Long-acting Injectable Antipsychotics (LAIs) Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Figure 9. Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country/Region (2023)

Figure 10. Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country/Region (2019, 2023 & 2030)

Figure 11. Product Picture of First-generation

Figure 12. Product Picture of Second-generation

Figure 13. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type in 2023

Figure 14. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Type (2019-2024)

Figure 15. Long-acting Injectable Antipsychotics (LAIs) Consumed in Schizophrenia

Figure 16. Global Long-acting Injectable Antipsychotics (LAIs) Market: Schizophrenia (2019-2024) & (K Units)

Figure 17. Long-acting Injectable Antipsychotics (LAIs) Consumed in Bipolar Disorder

Figure 18. Global Long-acting Injectable Antipsychotics (LAIs) Market: Bipolar Disorder (2019-2024) & (K Units)

Figure 19. Long-acting Injectable Antipsychotics (LAIs) Consumed in Other

Figure 20. Global Long-acting Injectable Antipsychotics (LAIs) Market: Other (2019-2024) & (K Units)

Figure 21. Global Long-acting Injectable Antipsychotics (LAIs) Sale Market Share by Application (2023)

Figure 22. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Application in 2023

Figure 23. Long-acting Injectable Antipsychotics (LAIs) Sales by Company in 2023 (K

Units)

Figure 24. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Company in 2023

Figure 25. Long-acting Injectable Antipsychotics (LAIs) Revenue by Company in 2023 (\$ millions)

Figure 26. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Company in 2023

Figure 27. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Geographic Region (2019-2024)

Figure 28. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Geographic Region in 2023

Figure 29. Americas Long-acting Injectable Antipsychotics (LAIs) Sales 2019-2024 (K Units)

Figure 30. Americas Long-acting Injectable Antipsychotics (LAIs) Revenue 2019-2024 (\$ millions)

Figure 31. APAC Long-acting Injectable Antipsychotics (LAIs) Sales 2019-2024 (K Units)

Figure 32. APAC Long-acting Injectable Antipsychotics (LAIs) Revenue 2019-2024 (\$ millions)

Figure 33. Europe Long-acting Injectable Antipsychotics (LAIs) Sales 2019-2024 (K Units)

Figure 34. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue 2019-2024 (\$ millions)

Figure 35. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales 2019-2024 (K Units)

Figure 36. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Revenue 2019-2024 (\$ millions)

Figure 37. Americas Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country in 2023

Figure 38. Americas Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Country (2019-2024)

Figure 39. Americas Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2019-2024)

Figure 40. Americas Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Application (2019-2024)

Figure 41. United States Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 42. Canada Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 43. Mexico Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 44. Brazil Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 45. APAC Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Region in 2023

Figure 46. APAC Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Region (2019-2024)

Figure 47. APAC Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2019-2024)

Figure 48. APAC Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Application (2019-2024)

Figure 49. China Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 50. Japan Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 51. South Korea Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 52. Southeast Asia Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 53. India Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 54. Australia Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 55. China Taiwan Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 56. Europe Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country in 2023

Figure 57. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Country (2019-2024)

Figure 58. Europe Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2019-2024)

Figure 59. Europe Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Application (2019-2024)

Figure 60. Germany Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 61. France Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 62. UK Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024

(\$ millions)

Figure 63. Italy Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 64. Russia Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 65. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country (2019-2024)

Figure 66. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2019-2024)

Figure 67. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Application (2019-2024)

Figure 68. Egypt Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 69. South Africa Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 70. Israel Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 71. Turkey Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 72. GCC Countries Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 (\$ millions)

Figure 73. Manufacturing Cost Structure Analysis of Long-acting Injectable Antipsychotics (LAIs) in 2023

Figure 74. Manufacturing Process Analysis of Long-acting Injectable Antipsychotics (LAIs)

Figure 75. Industry Chain Structure of Long-acting Injectable Antipsychotics (LAIs)

Figure 76. Channels of Distribution

Figure 77. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Forecast by Region (2025-2030)

Figure 78. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share Forecast by Region (2025-2030)

Figure 79. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share Forecast by Type (2025-2030)

Figure 80. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share Forecast by Type (2025-2030)

Figure 81. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share Forecast by Application (2025-2030)

Figure 82. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Long-acting Injectable Antipsychotics (LAIs) Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/GE85941B8D5BEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE85941B8D5BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970